

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Consideration of consultation responses on review proposal

Review of TA169; Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma and TA178; Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma

This guidance was issued in March 2009 (TA169) / August 2009 (TA178).

The review date for this guidance is June 2011 (deferred from February 2011 for TA169).

Background

At the GE meeting of 28 February 2012 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

Proposal put to consultees:	The guidance should be transferred to the 'static guidance list'.
Rationale for selecting this proposal	All companies involved state that there is no significant new evidence to warrant a review at this time. Consequently, TA169 and TA178 should be transferred to the static list of technology appraisals. The appraisals can be brought back into the active list of appraisals if NICE are informed at a later date of significant new evidence that could imply re-consideration of a review is needed.

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

Recommendation post consultation:	The guidance should be transferred to the 'static guidance list'.
--	---

Respondent	Response to proposal	Details	Comment from Technology Appraisals
Roche Products	Agree	Roche is not aware of any new evidence relevant to this guidance, and therefore agree with the Institute's proposal that TA169 and TA178 should be transferred to the static list of technology appraisals.	Comment noted.
GlaxoSmithKline	Agree	We are in agreement with NICE's proposal to move guidance reviews of TA169 and TA178 to a static list.	Comment noted.
Healthcare Improvement	No comment	Healthcare Improvement Scotland has no comment to make on the proposal to transfer this appraisal to the static list and we have noted this in our records.	Comment noted.

Respondent	Response to proposal	Details	Comment from Technology Appraisals
James Whale Fund for Kidney Cancer	Disagree	The Axis trial has demonstrated clear benefit for Axitinib over Sorafenib in patients who have failed Sunitinib. This is the first time one targeted drug has shown superiority over another targeted agent in kidney cancer. In the absence of and NICE approved 2nd line therapy in renal cancer patients, there is a desperate need for axitinib to help in the treatment of their disease.	Comment noted. A separate single technology appraisal of axitinib for the treatment of advanced renal cell carcinoma after failure of prior systemic treatment has been proposed as part of the NICE work programme in order to produce timely guidance on its use in the NHS.
Bayer Schering	Agree	We would support NICE's proposal to transfer TA169 and TA178 to the static list	Comment noted.
Medicines and Healthcare Products Regulatory Agency	No comment	We have no comments for this appraisal.	Comment noted.
National Cancer Research Institute / Royal College of Physicians / Royal College of Radiologists / Association of Cancer Physicians	Agree	The NCRI/RCP/RCR/ACP/JCCO agrees with the NICE proposal to move the guidance to the static list. Our experts are aware of no new evidence at present in this area.	Comment noted.

Respondent	Response to proposal	Details	Comment from Technology Appraisals
Royal College of Nursing	No comment	The feedback received from nurses working in this area of health suggest that there are no additional comments to be submitted on behalf of the Royal College of Nursing on the review of the above appraisal.	Comment noted.

No response received from:

<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Pfizer (sunitinib) (temsirolimus) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • British Kidney Patient Association • Cancer Black Care • Cancer Equality • Cancer52 • Chinese National Healthy Living Centre • Counsel and Care • Equalities National Council • Helen Rollason Heal Cancer Charity • Kidney Alliance • Kidney Cancer UK • Kidney Research UK • Macmillan Cancer Support 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • National Association of Primary Care • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium • Welsh Kidney Patients Association <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Novartis Pharmaceuticals (interleukin-2) • Roche Products (interferon alpha)
--	--

- Maggie's Centres
- Marie Curie Cancer Care
- Muslim Council of Britain
- Muslim Health Network
- National Kidney Federation
- Rarer Cancers Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Sue Ryder Care
- Tenovus

Professional groups

- Association of Renal Industries
- British Association for Services to the Elderly
- British Association of Urological Nurses
- British Geriatrics Society
- British Institute of Radiology
- British Oncological Association
- British Psychosocial Oncology Society
- British Renal Society
- Cancer Network Pharmacists Forum
- Cancer Research UK
- Renal Association
- Renal Pharmacy Group
- Royal College of General Practitioners
- Royal College of Pathologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- Society for DGH Nephrologists

Relevant research groups

- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Cancer Research Network
- National Institute for Health Research
- Research Institute of the Care of Older People

Assessment Group

- tbc
- National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

- National Collaborating Centre for Cancer

Associated Public Health Groups

- None

- | | |
|--|--|
| <ul style="list-style-type: none">• United Kingdom Clinical Pharmacy Association• United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none">• Department of Health• NHS Wakefield District• South Staffordshire NHS PCT• Welsh Government | |
|--|--|

GE paper sign-off: Frances Sutcliffe Associate Director – Technology Appraisals Programme 30 April 2012

Contributors to this paper:

Technical Lead: Matthew Dyer

Technical Adviser: Zoe Charles

Project Manager: Andrew Kenyon

30 April 2012